A Phase 1 Dose-escalation and Expansion Study of an Intratumorally Administered Dual STING Agonist (ONM-501) Alone and in Combination with Cemiplimab

ONM-501

Jun 2

Brad Good has been an endorsed Squarespace Expert since the beginning and has been working on the platform since 2008. He has helped hundreds of Squarespace customers with their websites.

http://www.bradgood.net

A Phase 1 Dose-escalation and Expansion Study of an Intratumorally Administered Dual STING Agonist (ONM-501) Alone and in Combination with Cemiplimab

Results from Part-1 of ON-5001: A Multi-center, Dose Escalation and Dose Finding Phase 1 Trial of ONM-501, a Dual-Acting STING Agonist

Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study